News X4 Pharmaceuticals, Inc.

Equities

XFOR

US98420X1037

Market Closed - Nasdaq Other stock markets 01:30:00 02/05/2024 am IST			5-day change	1st Jan Change
1.105 ^USD	-1.34%		-14.34%	+31.78%

30/04	HC Wainwright Adjusts Price Target on X4 Pharmaceuticals to $5 From $3, Maintains Buy Rating	MT
29/04	Pantherx® Rare Partner with X4 Pharmaceuticals Inc. for the Distribution of Xolremdi? (Mavorixafor), the First FDApproved Therapy Indicated for Use in Patients with Whim Syndrome	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/05	AQ
HC Wainwright Adjusts Price Target on X4 Pharmaceuticals to $5 From $3, Maintains Buy Rating	30/04	MT
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024	30/04	AQ
Pantherx® Rare Partner with X4 Pharmaceuticals Inc. for the Distribution of Xolremdi? (Mavorixafor), the First FDApproved Therapy Indicated for Use in Patients with Whim Syndrome	29/04	CI
X4 Pharmaceuticals' Xolremdi Approved by FDA For WHIM Syndrome	29/04	MT
Transcript : X4 Pharmaceuticals, Inc. - Special Call	29/04
X4 Pharmaceuticals Gets FDA Approval for Xolremdi Capsules	29/04	DJ
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome	29/04	AQ
X4 Pharmaceuticals, Inc. Announces FDA Approval of XOLREMDI (mavorixafor) Capsules, First Drug Indicated in Patients with Whim Syndrome	29/04	CI
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	03/04	AQ
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03/04	AQ
X4 Pharmaceuticals : Regulation FD Disclosure - Form 8-K	01/04	PU
X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences	01/04	AQ
Transcript : X4 Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 21, 2024	21/03
X4 Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03	CI
X4 Pharmaceuticals: Q4 Earnings Snapshot	21/03	AQ
North American Morning Briefing : Investors -2-	21/03	DJ
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update	21/03	AQ
X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024	12/03	AQ
Thinking about buying stock in Marpai, Axcelis Technologies, Amylyx Pharmaceuticals, Biomx, or X4 Pharmaceuticals?	11/03	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News X4 Pharmaceuticals, Inc.

Equities

XFOR

US98420X1037

Summary

Filters